The aims of this study were 1) to estimate the incremental cost-effectiveness ratio (ICER) of offering statins for primary prevention of CVD for each CVD risk group, and 2) to estimate the budget impact if the statins were prescribed to those people living with different CVD risks. This was a model-based economic evaluation. A Markov model was constructed to estimate the costs and benefits in terms of quality adjusted life year (QALY) gained by providing statins in comparison to a “null” or “do nothing” scenario. The study revealed that if a ceiling threshold is equal to 3 times that of Gross Domestic Product per capita or 300,000 Baht per QALY, a generic simvastatin is a cost-effective intervention for all people except those with less than 2.5% CV D risk. However, if the ceiling threshold is equal to 100,000 Baht per QAL Y, a generic simvastatin is still considered as a cost-effective intervention if it is offered to Thai people with > 30% CVD risk.